Currently out of the existing stock ratings of Matthew Barcus, 35 are a BUY (94.59%), 2 are a HOLD (5.41%).

Matthew Barcus

Work Performance Price Targets & Ratings Chart

Analyst Matthew Barcus, currently employed at CHARDAN CAPITAL, carries an average stock price target met ratio of 63.64% that have a potential upside of 67.25% achieved within 249 days.

Matthew Barcus’s has documented 68 price targets and ratings displayed on 11 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on QURE, Uniqure NV at 22-Jun-2023.

Wall Street Analyst Matthew Barcus

Analyst best performing recommendations are on IMVT (IMMUNOVANT ).
The best stock recommendation documented was for IMVT (IMMUNOVANT ) at 9/29/2022. The price target of $12 was fulfilled within 36 days with a profit of $6.62 (123.05%) receiving and performance score of 34.18.

Average potential price target upside

of $156.5 (41.57%) on PPBT (PURPLE BIOTECH).
of $35.85 (203.51%) on QURE (UNIQURE NV).
of $31.45 (80.95%) on XLO (XILIO DEVELOPMENT).

IMNM Immunome IMVT Immunovant VBLT Vascular Biogenics Ltd VINC Vincerx Pharma FIXX Homology Medicines ONCR Oncorus AMTI Applied Molecular Transport ANIX Anixa Biosciences QURE Uniqure NV XLO Xilio Development PPBT Purple Biotech

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

David Nierengarten (WEDBUSH)